- The FDA has granted accelerated approval to BeiGene Ltd's BGNE Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
- The accelerated approval is based on the overall response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- The recommended dose of Brukinsa is either 160 mg twice daily or 320 mg once daily, taken orally with or without food.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: BGNE stock is up 5.70% at $389.93 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
